In accordance, FACS analysis of CD34+ HSPCs from CML patients revealed a significantly higher LIGHT expression and a trend to a higher expression of LTβR than in control CD34+ HSPCs (Fig. 8b). The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.